Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein–Protein Interactions-Reference-Cited by-同舟云学术

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein–Protein Interactions

Published:2021-10-29 Issue:21 Volume:64 Page:15973-15990
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Bobone Sara¹^ORCID,Pannone Luca²³,Biondi Barbara⁴^ORCID,Solman Maja⁵,Flex Elisabetta³,Canale Viviana Claudia¹^ORCID,Calligari Paolo¹,De Faveri Chiara⁶,Gandini Tommaso⁶,Quercioli Andrea¹^ORCID,Torini Giuseppe¹,Venditti Martina²,Lauri Antonella²,Fasano Giulia²,Hoeksma Jelmer⁵,Santucci Valerio¹^ORCID,Cattani Giada¹,Bocedi Alessio¹,Carpentieri Giovanna²³,Tirelli Valentina⁷,Sanchez Massimo⁷,Peggion Cristina⁶^ORCID,Formaggio Fernando⁴⁶,den Hertog Jeroen⁴⁸^ORCID,Martinelli Simone³,Bocchinfuso Gianfranco¹^ORCID,Tartaglia Marco²,Stella Lorenzo¹^ORCID

Affiliation:

1. Department of Chemical Science and Technologies, University of Rome Tor Vergata, Rome 00133, Italy

2. Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome 00146, Italy

3. Dipartimento di Oncologia e Medicina Molecolare, Istituto Superiore di Sanità, Rome 00161, Italy

4. Institute of Biomolecular Chemistry, Padova Unit, CNR, Padova 35131, Italy

5. Hubrecht institute-KNAW and University Medical Center Utrecht, Utrecht 3584 CT, The Netherlands

6. Department of Chemical Sciences, University of Padova, Padova 35131, Italy

7. Centre of Core Facilities, Istituto Superiore di Sanità, Rome 00161, Italy

8. Institute of Biology Leiden, Leiden University, Leiden 2333 BE, The Netherlands

Funder

Regione Lazio

Partnership for Advanced Computing in Europe AISBL

Associazione Italiana per la Ricerca sul Cancro

Ministero della Salute

Ministero dell'Istruzione, dell'Universit?? e della Ricerca

CINECA

European Program on Rare Diseases

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01371

Reference96 articles.

1. SHP2 sails from physiology to pathology

2. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2

3. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia

4. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia

5. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

2. Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules;European Journal of Medicinal Chemistry;2024-09

3. Design, Synthesis and Antitumor Activity of a Novel Class of SHP2 Allosteric Inhibitors with a Furanyl Amide-Based Scaffold;Journal of Medicinal Chemistry;2024-07-27

4. Discovery of Novel Allosteric SHP2 Inhibitor Using Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation, and Principal Component Analysis;Pharmaceuticals;2024-07-12

5. Assessment of the FRET-based Teen sensor to monitor ERK activation changes preceding morphological defects in a RASopathy zebrafish model and phenotypic rescue by MEK inhibitor;Molecular Medicine;2024-04-09